^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Kinase inhibitor

    Related drugs:
    28d
    OMX-0407-101: A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically (clinicaltrials.gov)
    P1/2, N=188, Active, not recruiting, iOmx Therapeutics AG | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2026 --> Jun 2026
    Enrollment closed • Trial primary completion date
    |
    OMX-0407
    1m
    Effects of the Pharmacological Modulation of NRF2 in Cancer Progression. (PubMed, Medicina (Kaunas))
    In contrast, NRF2 activators, such as bardoxolone methyl (CDDO-Me), sulforaphane, and dimethyl fumarate, exhibit chemopreventive effects by enhancing detoxification and mitigating oxidative DNA damage during early tumorigenesis...Therefore, understanding the temporal and contextual effects of NRF2 signaling is crucial for therapeutic design. The aim of this review is to examine how pharmacological modulation of NRF2 influences the invasive and metastatic dimensions of tumor progression, in addition to discussing its potential integration into TNM-based prognostic and treatment frameworks.
    Review • Journal
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    KEAP1 mutation • NFE2L2 mutation
    1m
    Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, Washington University School of Medicine | Trial primary completion date: Dec 2025 --> Apr 2026
    Trial primary completion date
    |
    Fakzynja (defactinib)
    1m
    Synthetic Oleanane Triterpenoids Reduce Tumor Growth and Promote an Anti-Tumor Immune Response Independent of Cancer KEAP1 Mutational Status. (PubMed, Antioxidants (Basel))
    Similarly, subcutaneous KEAP1 KO tumors were larger and more immune-suppressed compared to WT tumors. Both CDDO-Me and omaveloxolone reduced the tumor burden and improved immune cell phenotypes within the TIME independent of KEAP1 mutational status.
    Journal
    |
    KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    KEAP1 mutation
    |
    Skyclarys (omaveloxolone)
    1m
    Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) (clinicaltrials.gov)
    P1/2, N=42, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    irinotecan • cirtuvivint (SM08502)
    2ms
    NRF2 upregulation by CDDO-Me protects AC16 human cardiomyocytes against doxorubicin-induced toxicity. (PubMed, Biomed Pharmacother)
    RNA-seq analysis was also utilised to highlight the molecular mechanisms underpinning the effects DOX in AC16 cells and the CDDO-mediated mitigation of cardiotoxicity. This study provides novel insight into NRF2 dynamics in the widely utilised AC16 cells whilst further elucidating the molecular mechanisms contributing to DOX cardiotoxicity and potential NRF2-orchestrated defence.
    Journal
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    doxorubicin hydrochloride
    2ms
    Pharmacogenomic and Circulating Biomarkers for CDK4/6 Inhibitors (clinicaltrials.gov)
    P=N/A, N=100, Enrolling by invitation, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    3ms
    Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=20, Suspended, City of Hope Medical Center | Recruiting --> Suspended
    Trial suspension
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • azacitidine • Stivarga (regorafenib)
    3ms
    Identification and Verification of Immune Metabolism-Related Biomarkers and Immune Infiltration Landscape for Pediatric Opsoclonus Myoclonus Ataxia Syndrome in Neuroblastoma. (PubMed, CNS Neurosci Ther)
    Four immune metabolism-associated diagnostic genes were identified, including TRAF3IP2, RIPK1, KEAP1, and DPP4 for OMAS.
    Journal
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • RIPK1 (Receptor Interacting Serine/Threonine Kinase 1)
    3ms
    Development of a leucine aminopeptidase-activatable co-prodrug from CDDO-Me and ligustrazine for synergistic treatment of liver injury. (PubMed, Bioorg Chem)
    Furthermore, CHL reduced p-p65 expression by 5-fold, indicating its effective inhibition of NF-κB transcriptional activity and thereby alleviating inflammatory responses. Therefore, the LAP-activable co-prodrug CHL holds promising potential as a candidate for the synergistic treatment of liver injury.
    Journal
    |
    NQO1 (NAD(P)H dehydrogenase, quinone 1) • RELA (RELA Proto-Oncogene)
    3ms
    Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1, N=151, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Oct 2025 | Trial primary completion date: May 2026 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    everolimus • Caprelsa (vandetanib)
    4ms
    A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, EIP Pharma Inc | Recruiting --> Active, not recruiting
    Enrollment closed